MiNK Therapeutics INKT
NASDAQ INKT
$10.06 -0.56 (-5.27%)
At close: Oct 22, 2026 · 4:00 PM EDT

MiNK Therapeutics (INKT) Long-Term Debt Repayments (2026)

Updated

MiNK Therapeutics' Long-Term Debt Repayments came in at $5 million for Q1 2026.

Analysis

MiNK Therapeutics (INKT) Long-Term Debt Repayments (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 873.00 Mn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 1.00 Mn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 2.00 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn 5.00 Mn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 20.00 Mn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 2.46 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn -
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn 17.00 Mn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn -
10 MiNK Therapeutics 51.69 Mn 10.50 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 5.00 Mn
API Access

MiNK Therapeutics Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=INKT&period=max&api_key=YOUR_API_KEY